Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.15
    +1.25 (+1.53%)
     

  • GOLD FUTURES

    2,343.40
    -3.00 (-0.13%)
     

  • DOW

    38,480.01
    +240.03 (+0.63%)
     

  • Bitcoin GBP

    53,652.18
    +472.71 (+0.89%)
     

  • CMC Crypto 200

    1,435.86
    +21.10 (+1.49%)
     

  • NASDAQ Composite

    15,672.08
    +220.77 (+1.43%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Novavax CFO Greg Covino to step down

Reuters
·1-min read
FILE PHOTO: A car drives past the sign for vaccine developer Novavax at the company's headquarters in Gaithersburg

(Reuters) - Novavax Inc said on Tuesday Greg Covino is stepping down as the chief financial officer due to personal reasons and would become an executive adviser to the U.S. vaccine developer.

Chief Business Officer John Trizzino will serve as the finance chief in the interim, with a search underway for Covino's replacement.

The company also said it had brought in Troy Morgan as its chief compliance officer from EMD Serono Inc, the biopharmaceutical arm of Germany's Merck KGaA in the United States and Canada. It also promoted Chief Scientist Gale Smith to senior vice president.

Novavax earlier on Tuesday said it had pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages.

ADVERTISEMENT

The company could receive UK regulatory authorization for its COVID-19 vaccine as early as this month after releasing impressive UK trial data. It expects U.S. clearance as early as May.

(Reporting by Dania Nadeem and Praveen Paramasivam in Bengaluru; Editing by Devika Syamnath)